Scienture Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $115.68M
- P/E (TTM)
- –
- Dividend yield
- –
About Scienture
Pharmaceutical Preparations, SIC 2834
Scienture Holdings, Inc. is a clinical-stage biopharmaceutical company focused on the development of pharmaceutical products and drug-device combination therapies. The company maintains an active development pipeline comprising multiple drug candidates, including SCN-102, SCN-104, SCN-106, and SCN-107, alongside formulations such as ARBLI losartan oral potassium suspension. Through strategic transactions and licensing arrangements, it advances proprietary product programs aimed at patients and healthcare providers requiring specialized drug treatments.
The company's operations encompass development programs and agreements primarily within the United States. Its commercial activities include relationships with institutional partners, lenders, and healthcare-focused collaborators such as Softell Inc., Micro Merchant Systems, and Superlatus. Scienture Holdings maintains its corporate headquarters at 20 Austin Boulevard in Commack, New York.
Summary of the business section of Scienture's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Scienture Holdings, Inc.
- Headquarters
- Commack, NY
- Address
- 20 Austin Blvd. 11725
- Phone
- (800) 261-0281
- Employees
- 8, Dec 31, 2023
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- CM3 Advisory, San Diego, California
Stock & identifiers
- Ticker
- SCNX
- Exchange
- Nasdaq
- Shares outstanding
- 41M, Aug 13, 2026
- Public float
- $10.20M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, Oct 5, 2026; 1-for-15 reverse, Aug 18, 2023; 1-for-15 reverse, Jun 22, 2023; 1-for-6 reverse, Mar 30, 2020
- SEC CIK
- 1382574
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Hariharan Shankar | Co-CEO & Chairman, Director | 3,890,383 |
| Mani Narasimhan | President & Co-CEO, Director | 2,945,515 |
| Eric Michael Sherb | Chief Financial Officer | 0 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Ajjarapu, Dr. Hariharan, and Dr. Mani. | $2.53M | $2.26M | $64.17K | $16 | – |
| FY2025 Peo | $2.53M | – | $64.17K | $16 | – |
| FY2024 Mr. Ajjarapu, Dr. Hariharan, and Dr. Mani. | $570.58K | $650.58K | $409.46K | $187 | – |
| FY2024 Peo | $570.58K | – | $409.46K | $187 | – |
| FY2023 Mr. Ajjarapu | $628.01K | $628.01K | $193.65K | $87 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“Currently, we have approximately 8 full-time employees.”
Corporate history
Events identified from SEC filings